Study #2023-0284
A phase 3, randomized, double-blind, active-comparator-controlled clinical study of adjuvant MK-7684A (Vibostolimab with Pembrolizumab) versus adjuvant Pembrolizumab in participants with high-risk stage II-IV melanoma (KEYVIBE-010).
MD Anderson Study Status
Not Accepting
Treatment Agent
Pembrolizumab/Vibostolimab
Description
The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The primary hypothesis is that pembrolizumab/vibostolimab is superior to pembrolizumab with respect to RFS as assessed by the investigator in participants with high-risk resected Stage IIB, IIC, III and IV melanoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Melanoma
Study phase:
Phase III
Physician name:
Hussein Tawbi
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-877-424-0935
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.